Chief Medical Officer Roope Sihvola joins Silmäasema’s Management Team

Silmäasema Oyj                
Stock exchange release                         
17 September 2019 at 4:15 p.m. EET

Roope Sihvola (M.D., ophthalmologist), Chief Medical Officer at Silmäasema, has been appointed as a member of Silmäasema’s Management Team. He will be responsible for the clinical quality of Silmäasema’s operations and cooperation between doctors and for developing treatment processes within the eye healthcare chain and in hospital operations. The Chief Medical Officer cooperates closely with the doctors working as sole proprietors at Silmäasema.

“Silmäasema’s good eyesight service and care chain extends from eye examinations performed by opticians to demanding eye surgery. We are seeking to strengthen customer focus, internal cooperation and operational efficiency throughout the chain while also ensuring high clinical quality at all times. The Chief Medical Officer’s role in the Management Team supports this goal effectively,” says CEO Jussi Salminen.

Silmäasema’s Management Team consists of Jussi Salminen (CEO), Sari Nordblad (CFO), Tapani Kyrki (Business Director), Jyrki Alamäki (Sales Director), Sirkkaliisa Kulmala (HR Director) and Roope Sihvola (Chief Medical Officer).

SILMÄASEMA OYJ

Jussi Salminen
CEO

For further information, please contact:

CEO Jussi Salminen, tel. +358 40 834 5818
Chief Medical Officer, Roope Sihvola, tel. +358 50 501 1920

Mikko Merisaari, Head of Communications and Investor Relations, tel. +358 50 521 4055

Silmäasema is a Finnish company, which offers a full range of products and services for optical retail and eye healthcare nationwide. Silmäasema is Finland’s largest private eye clinic chain offering eye surgeries and the second-largest optical retail chain in the country. The Silmäasema chain has close to 150 stores and 13 eye clinics in Finland and nine stores in Estonia. The Silmäasema chain employs more than 1,000 eyesight and eye healthcare professionals. The Silmäasema Group’s net sales were EUR 122.9 million and its adjusted EBITDA was EUR 11.8 million in 2018.